HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Hyperaldosteronism in the acute phase of myocardial infarction. Effects of its treatment on the prevention of ventricular fibrillation].

Abstract
Many metabolic and hormonal changes are observed during the acute phase of myocardial infarction (glucose metabolism, lipoproteins...). Mineralocorticoid function may also be disturbed but there have been few studies of this problem. The aim of this study was to confirm the elevation of serum aldosterone during the acute phase of myocardial infarction and to determine the effects of antialdosterone treatment in these patients. Hyperaldosteronism was confirmed in 74% of 72 consecutive patients admitted for acute myocardial infarction, in 85% if patients previously treated by an antialdosterone drug or admitted after the acute phase are excluded, and in 96% if patients with cardiac failure are included. One thousand consecutive patients admitted for myocardial infarction were given an antialdosterone agent systematically (intravenous potassium canrenoate , 600 mg daily for 5 days). The serum and red blood cell potassium concentrations rose, the number of ventricular extrasystoles and the administration of anti-arrhythmic drugs fell, and, above all, the prevalence of ventricular fibrillation decreased significantly: 0,8% (p less than 0,001), compared with comparable previously reported series.
AuthorsB Denis, R Dimitriou, J Machecourt, J E Wolf, E Page, J P Reboud
JournalArchives des maladies du coeur et des vaisseaux (Arch Mal Coeur Vaiss) Vol. 77 Spec No Pg. 35-40 (Apr 1984) ISSN: 0003-9683 [Print] France
Vernacular TitleL'hyperaldostéronisme de l'infarctus du myocarde à la phase aiguë. Incidence de son traitement sur la prévention de la fibrillation ventriculaire.
PMID6428361 (Publication Type: Clinical Trial, English Abstract, Journal Article)
Chemical References
  • Anti-Arrhythmia Agents
  • Pregnadienes
  • Spironolactone
  • Canrenoic Acid
  • Heparin
Topics
  • Acute Disease
  • Adult
  • Aged
  • Anti-Arrhythmia Agents (therapeutic use)
  • Canrenoic Acid (therapeutic use)
  • Clinical Trials as Topic
  • Female
  • Heparin (therapeutic use)
  • Humans
  • Hyperaldosteronism (drug therapy, etiology)
  • Male
  • Middle Aged
  • Myocardial Infarction (complications, metabolism)
  • Pregnadienes (therapeutic use)
  • Spironolactone (therapeutic use)
  • Ventricular Fibrillation (prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: